12.12.19
Charles River Laboratories International, Inc. will provide clients exclusive access to the new Cosmic antibody library launched by Distributed Bio, Inc., a global provider of computational optimization of fully human monoclonal antibody libraries.
Distributed Bio’s new Cosmic antibody library encompasses over one-hundred billion fully human antibodies, computationally optimized for therapeutic developability and complementarity-determining regions (CDRs) sourced and incorporated at specific frequencies for maximum library diversity.
Cosmic antibodies are entirely human by design with therapeutically favorable, unmutated frameworks. This phage-display antibody library was designed with immunogenicity in mind, the result is a library of leads with highly attractive profiles including nano- to picomolar potency, high expression levels, thermostability, non-immunogenicity, and soluble, aggregation-resistant features.
In 2018, Distributed Bio entered an exclusive partnership with Charles River providing access to its antibody libraries and integrated antibody optimization technologies. A combination of Distributed Bio’s antibody libraries and Charles River’s drug development expertise creates a unique platform for therapeutic antibody discovery and development. The partnership aims to continue to increase the probability of success for delivering high-quality antibody candidates.
“The new Cosmic antibody library will provide our clients with access to a truly differentiated library, with delivery of exclusive antibody leads in just three months—substantially reducing the risk of first to file,” said Birgit Girshick, corporate executive vice president, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River.
“By providing Charles River’s clients exclusive access to the Cosmic antibody library, we are excited to help increase success in early drug discovery by delivering qualified leads. Leveraging our revolutionary antibody discovery and engineering platforms and Charles River’s downstream capabilities, our partnership delivers a comprehensive research experience from idea to clinic,” said Jacob Glanville, Ph.D., founding partner, chief executive officer, and president at Distributed Bio.
Distributed Bio’s new Cosmic antibody library encompasses over one-hundred billion fully human antibodies, computationally optimized for therapeutic developability and complementarity-determining regions (CDRs) sourced and incorporated at specific frequencies for maximum library diversity.
Cosmic antibodies are entirely human by design with therapeutically favorable, unmutated frameworks. This phage-display antibody library was designed with immunogenicity in mind, the result is a library of leads with highly attractive profiles including nano- to picomolar potency, high expression levels, thermostability, non-immunogenicity, and soluble, aggregation-resistant features.
In 2018, Distributed Bio entered an exclusive partnership with Charles River providing access to its antibody libraries and integrated antibody optimization technologies. A combination of Distributed Bio’s antibody libraries and Charles River’s drug development expertise creates a unique platform for therapeutic antibody discovery and development. The partnership aims to continue to increase the probability of success for delivering high-quality antibody candidates.
“The new Cosmic antibody library will provide our clients with access to a truly differentiated library, with delivery of exclusive antibody leads in just three months—substantially reducing the risk of first to file,” said Birgit Girshick, corporate executive vice president, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River.
“By providing Charles River’s clients exclusive access to the Cosmic antibody library, we are excited to help increase success in early drug discovery by delivering qualified leads. Leveraging our revolutionary antibody discovery and engineering platforms and Charles River’s downstream capabilities, our partnership delivers a comprehensive research experience from idea to clinic,” said Jacob Glanville, Ph.D., founding partner, chief executive officer, and president at Distributed Bio.
